leadf
logo-loader
viewProactive Group

Destiny Pharma confirms plans to float on London's junior market AIM

Destiny Pharma will use the funds of its placing to progress its leading drug XF-73 to Phase III pivotal studies

biotech
Destiny Pharma's leading drug targets antibiotic-resistant bacterial infections in hospitals

Destiny Pharma has announced its plans for an initial public offering, making it only the second biotech company to float on the London stock market this year.

The clinical stage biotechnology company, focused on the development of new anti-microbial drugs, said it has applied for the admission of its ordinary shares to trading on the Alternative Investment Market (AIM).

The amount of capital raised through the placing will be determined in coming days, the company said, adding that it will use the funds to progress its leading drug XF-73 to Phase III pivotal studies in the prevention of post-surgical Staphylococcus aureus infections during 2019.

“This should be a key value inflection point as, if successful, our drug would be the first to be specifically labelled for this new US Food and Drug Administration sanctioned indication; a market we believe to be worth a billion dollars in the US alone and growing,” said chief executive, Neil Clark.

The X-73 drug targets antibiotic-resistant bacterial infections in hospitals. It represents the only antibacterial drug known to resist 55 repeat exposures to superbug, Methicillin Resistant Staphylococcus aureus (MRSA), a bacteria that is resistant to many antibiotics and can cause a variety of problems such as skin infections, sepsis and pneumonia.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Loop Insights getting ready to rumble as platform wallet being used by the...

Loop Insights (CVE: MTRX- OTCQB: RACMF) CEO Rob Anson joined Steve Darling from Proactive with big news that Loop's Wallet pass platform will engage global boxing fans during the WBC super-middleweight championship fight, featuring champion Saul "Canelo" Alvarez and challenger Avni...

23 hours, 35 minutes ago

2 min read